MX359292B - Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones y modulacion de biomarcadores de energia. - Google Patents
Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones y modulacion de biomarcadores de energia.Info
- Publication number
- MX359292B MX359292B MX2012009599A MX2012009599A MX359292B MX 359292 B MX359292 B MX 359292B MX 2012009599 A MX2012009599 A MX 2012009599A MX 2012009599 A MX2012009599 A MX 2012009599A MX 359292 B MX359292 B MX 359292B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disclosed
- treatment
- biomakers
- redox
- Prior art date
Links
- 208000012268 mitochondrial disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024412 Friedreich ataxia Diseases 0.000 abstract 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 abstract 2
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 abstract 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- LTVDFSLWFKLJDQ-IEOSBIPESA-N 2-[(3r,7r,11r)-3-hydroxy-3,7,11,15-tetramethylhexadecyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LTVDFSLWFKLJDQ-IEOSBIPESA-N 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000032274 Encephalopathy Diseases 0.000 abstract 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 abstract 1
- LTVDFSLWFKLJDQ-DKGMKSHISA-N alpha-Tocopherolquinone Natural products CC(C)CCC[C@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LTVDFSLWFKLJDQ-DKGMKSHISA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/06—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation
- C07C37/07—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation with simultaneous reduction of C=O group in that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
- C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/245—Halogenated derivatives monocyclic polyhydroxylic containing halogens bound to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C07C46/02—Preparation of quinones by oxidation giving rise to quinoid structures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C07C46/02—Preparation of quinones by oxidation giving rise to quinoid structures
- C07C46/06—Preparation of quinones by oxidation giving rise to quinoid structures of at least one hydroxy group on a six-membered aromatic ring
- C07C46/08—Preparation of quinones by oxidation giving rise to quinoid structures of at least one hydroxy group on a six-membered aromatic ring with molecular oxygen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/02—Quinones with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/02—Quinones with monocyclic quinoid structure
- C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68682605P | 2005-06-01 | 2005-06-01 | |
| US70181505P | 2005-07-21 | 2005-07-21 | |
| US77602806P | 2006-02-22 | 2006-02-22 | |
| PCT/US2006/021295 WO2006130775A2 (en) | 2005-06-01 | 2006-06-01 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX359292B true MX359292B (es) | 2018-09-24 |
Family
ID=37307328
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009599A MX359292B (es) | 2005-06-01 | 2006-06-01 | Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones y modulacion de biomarcadores de energia. |
| MX2007015006A MX2007015006A (es) | 2005-06-01 | 2006-06-01 | Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones o modulacion de biomarcadores de energia. |
| MX2010011492A MX2010011492A (es) | 2005-06-01 | 2010-10-19 | Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones y modulacion de biomarcadores de energia. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007015006A MX2007015006A (es) | 2005-06-01 | 2006-06-01 | Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones o modulacion de biomarcadores de energia. |
| MX2010011492A MX2010011492A (es) | 2005-06-01 | 2010-10-19 | Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones y modulacion de biomarcadores de energia. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9447006B2 (enExample) |
| EP (4) | EP2564843B1 (enExample) |
| JP (6) | JP2008542389A (enExample) |
| CA (2) | CA2996149A1 (enExample) |
| DK (3) | DK2564843T3 (enExample) |
| EA (2) | EA035619B1 (enExample) |
| ES (3) | ES2619303T3 (enExample) |
| HU (1) | HUE033304T2 (enExample) |
| MX (3) | MX359292B (enExample) |
| PL (3) | PL1888059T3 (enExample) |
| PT (2) | PT1888059E (enExample) |
| SI (1) | SI1888059T1 (enExample) |
| WO (1) | WO2006130775A2 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EA035619B1 (ru) | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| US9050005B2 (en) | 2005-08-25 | 2015-06-09 | Synapse Biomedical, Inc. | Method and apparatus for transgastric neurostimulation |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| EP2332534B1 (en) * | 2006-02-22 | 2018-11-14 | Bioelectron Technology Corporation | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers |
| US8676323B2 (en) | 2006-03-09 | 2014-03-18 | Synapse Biomedical, Inc. | Ventilatory assist system and methods to improve respiratory function |
| US20080097153A1 (en) * | 2006-08-24 | 2008-04-24 | Ignagni Anthony R | Method and apparatus for grasping an abdominal wall |
| WO2008098001A2 (en) | 2007-02-05 | 2008-08-14 | Synapse Biomedical, Inc. | Removable intramuscular electrode |
| US9820671B2 (en) | 2007-05-17 | 2017-11-21 | Synapse Biomedical, Inc. | Devices and methods for assessing motor point electromyogram as a biomarker |
| US8478412B2 (en) | 2007-10-30 | 2013-07-02 | Synapse Biomedical, Inc. | Method of improving sleep disordered breathing |
| US8428726B2 (en) | 2007-10-30 | 2013-04-23 | Synapse Biomedical, Inc. | Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system |
| PL2220030T3 (pl) | 2007-11-06 | 2016-07-29 | Bioelectron Tech Corp | Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| EP2262519A4 (en) * | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS |
| WO2009111576A2 (en) * | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2303824B1 (en) * | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| EA201101576A1 (ru) * | 2009-04-28 | 2012-04-30 | Эдисон Фармасьютикалз, Инк. | Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний |
| CA2777479C (en) * | 2009-04-28 | 2017-10-17 | Ptc Therapeutics, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| NO2470168T3 (enExample) * | 2009-08-26 | 2018-06-30 | ||
| EP2493482B1 (en) * | 2009-10-27 | 2014-04-30 | Bernd-Michael Löffler | Therapeutic gas for the treatment of mitochondrial disorders |
| CA2797644A1 (en) * | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| EA201201268A1 (ru) * | 2010-03-09 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Синтез производных альфа-токоферолхинона и способы их применения |
| EA201201374A1 (ru) * | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
| AU2011245384C1 (en) * | 2010-04-27 | 2016-09-01 | Bioelectron Technology Corporation | Formulations of quinones for the treatment of ophthalmic diseases |
| WO2012019032A1 (en) * | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
| US20130345312A1 (en) * | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| EP2606022A2 (en) | 2010-08-16 | 2013-06-26 | Santhera Pharmaceuticals (Schweiz) AG | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| HRP20161407T1 (hr) | 2010-08-16 | 2016-12-02 | Santhera Pharmaceuticals (Schweiz) Ag | Derivati benzokinona za liječenje mitohondrijskih bolesti oka |
| WO2012068552A1 (en) * | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| WO2012136680A1 (en) * | 2011-04-07 | 2012-10-11 | Akzo Nobel Chemicals International B.V. | Process for the production of dialkyl zinc and dialkyl aluminium halide |
| US9464016B2 (en) * | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| ES2795798T3 (es) * | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
| CA2842486C (en) | 2011-07-19 | 2022-09-06 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| EP2573063A1 (en) | 2011-09-23 | 2013-03-27 | DSM IP Assets B.V. | Process for preparing chiral quinone |
| CA2883879A1 (en) * | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| JP2016515526A (ja) | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| WO2014194292A1 (en) | 2013-05-31 | 2014-12-04 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
| CN104387253A (zh) * | 2014-11-03 | 2015-03-04 | 南昌大学 | α–生育醌在治疗糖尿病或肥胖症药物中的应用 |
| EP3233819A1 (en) | 2014-12-16 | 2017-10-25 | Bioelectron Technology Corporation | Methods for chiral resolution of trolox |
| HUE058877T2 (hu) | 2014-12-16 | 2022-09-28 | Ptc Therapeutics Inc | (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai |
| JP2018502127A (ja) | 2015-01-12 | 2018-01-25 | バイオエレクトロン テクノロジー コーポレイション | 放射線被曝に対する防護のためのキノン |
| ES3033538T3 (en) * | 2015-10-08 | 2025-08-05 | Khondrion Ip B V | Novel compounds for treating mitochondrial disease |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CA3011293A1 (en) | 2016-01-12 | 2017-07-20 | Ptc Therapeutics, Inc. | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| WO2018129411A1 (en) | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
| WO2018191732A1 (en) | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| US12502408B2 (en) | 2018-07-22 | 2025-12-23 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy for primary mitochondrial diseases |
| HUE066196T2 (hu) | 2018-10-17 | 2024-07-28 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére |
| CN109704938B (zh) * | 2018-12-19 | 2022-02-22 | 江南大学 | 一种生育酚单体制备对醌的方法 |
| US11471683B2 (en) | 2019-01-29 | 2022-10-18 | Synapse Biomedical, Inc. | Systems and methods for treating sleep apnea using neuromodulation |
| IL291898B1 (en) * | 2019-10-04 | 2026-06-01 | Stealth Biotherapeutics Inc | Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders |
| WO2021077034A1 (en) | 2019-10-18 | 2021-04-22 | Ptc Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders |
| CA3176909A1 (en) | 2020-04-03 | 2021-10-07 | Stealth Biotherapeutics Inc. | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia |
| AU2022291142A1 (en) * | 2021-06-10 | 2023-12-21 | Stealth Biotherapeutics Inc. | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia |
| EP4366700A1 (en) | 2021-07-08 | 2024-05-15 | PTC Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (239)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856414A (en) | 1958-10-14 | Oxidation of alpha-tocopherol | ||
| US2398418A (en) | 1943-08-27 | 1946-04-16 | Louis F Fieser | Introduction of organic radicals into quinones |
| FR1201200A (fr) | 1958-08-08 | 1959-12-29 | Sogespar S A | Procédé de fabrication de l'alpha tocophéryl-quinone |
| US3071512A (en) | 1959-01-26 | 1963-01-01 | Sogespar S A | New hypotensive pharmaceutical preparation containing alpha-tocopheryl-quinone |
| US3406188A (en) | 1964-03-27 | 1968-10-15 | Sun Oil Co | Preparation of alpha-tocopherylquinone |
| FR5531M (enExample) | 1966-02-08 | 1967-11-13 | ||
| FR1536576A (fr) | 1967-08-29 | 1968-08-16 | Eastman Kodak Co | Procédés d'enrichissement et de fractionnement de mélanges à base de tocophérols |
| US3728363A (en) | 1970-03-17 | 1973-04-17 | Takeda Chemical Industries Ltd | Quinone derivatives |
| US3705239A (en) | 1970-10-16 | 1972-12-05 | Roy B Gregory | Pain removing compositions and methods |
| UST917001I4 (en) | 1971-12-02 | 1973-12-04 | Defensive publication | |
| JPS4875564U (enExample) | 1971-12-21 | 1973-09-19 | ||
| JPS4875564A (enExample) | 1972-01-08 | 1973-10-11 | ||
| JPS4988862U (enExample) | 1972-11-20 | 1974-08-01 | ||
| JPS4988862A (enExample) | 1972-12-29 | 1974-08-24 | ||
| JPS5245698B2 (enExample) | 1973-04-06 | 1977-11-17 | ||
| FR2235679B1 (enExample) | 1973-07-02 | 1978-07-21 | Takeda Chemical Industries Ltd | |
| US3909376A (en) | 1974-12-04 | 1975-09-30 | Basf Ag | Electrolytic manufacture of alkyl-substituted hydroquinones |
| US3939376A (en) * | 1974-12-26 | 1976-02-17 | Union Carbide Corporation | Alignment spring counteracting antenna type getter effect on electron gun alignment |
| JPS52111576A (en) | 1976-03-15 | 1977-09-19 | Teijin Ltd | Synthesis of 5,7,8-trimethyl-3,4-dehydrotocotrienol |
| JPS52130922U (enExample) | 1976-03-31 | 1977-10-05 | ||
| JPS5938203B2 (ja) | 1976-04-26 | 1984-09-14 | エーザイ株式会社 | 補酵素ｑを主成分とする脳循環障害治療剤 |
| US4201879A (en) | 1977-05-16 | 1980-05-06 | Hoffmann-La Roche Inc. | Hydroquinones |
| US4153614A (en) | 1978-05-12 | 1979-05-08 | Hoffmann-La Roche Inc. | Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein |
| LU77344A1 (enExample) | 1977-05-16 | 1979-01-19 | ||
| US4185154A (en) | 1977-05-17 | 1980-01-22 | Hoffmann-La Roche, Inc. | Synthesis of vitamin E |
| US4310465A (en) | 1977-05-17 | 1982-01-12 | Hoffmann-La Roche Inc. | Synthesis of vitamin E and quinone intermediates |
| US4243598A (en) | 1977-05-17 | 1981-01-06 | Hoffmann-La Roche Inc. | Synthesis of vitamin E |
| US4201726A (en) | 1977-05-17 | 1980-05-06 | Hoffmann-La Roche Inc. | Synthesis of Vitamin E |
| US4127608A (en) | 1977-05-17 | 1978-11-28 | Hoffmann-La Roche Inc. | Synthesis of Vitamin E |
| JPS5818374Y2 (ja) | 1978-07-29 | 1983-04-14 | 日本電気ホームエレクトロニクス株式会社 | 複合テレビジヨン受像機のキヤビネツト |
| JPS5640651A (en) | 1979-09-12 | 1981-04-16 | Takeda Chem Ind Ltd | Quinone compound and its preparation |
| JPS567734A (en) | 1979-06-28 | 1981-01-27 | Takeda Chem Ind Ltd | Preparation of quinone derivative |
| JPS56147746A (en) | 1980-04-15 | 1981-11-16 | Takeda Chem Ind Ltd | Quinones and their preparation |
| JPS567737A (en) | 1979-07-02 | 1981-01-27 | Takeda Chem Ind Ltd | Physiologically active quinone and its preparation |
| JPS5697223A (en) | 1979-12-30 | 1981-08-05 | Takeda Chem Ind Ltd | Tissue metabolism activator |
| JPS56140943A (en) | 1980-04-07 | 1981-11-04 | Takeda Chem Ind Ltd | Preparation of organic compound |
| JPH0193554A (ja) | 1980-04-07 | 1989-04-12 | Takeda Chem Ind Ltd | 有機化合物 |
| US4393075A (en) | 1980-04-14 | 1983-07-12 | Takeda Chemical Industries, Ltd. | Quinone compounds and their use in suppressing the production of SRS-A in mammals |
| JPS5750935A (en) | 1980-09-12 | 1982-03-25 | Otsuka Pharmaceut Co Ltd | 1,4-benzoquinone derivative |
| JPS57131735A (en) | 1981-02-09 | 1982-08-14 | Takeda Chem Ind Ltd | Preparation of quinones |
| JPS57183782A (en) | 1981-04-30 | 1982-11-12 | Sumitomo Chem Co Ltd | Preparation of coumarone compound |
| JPS5818374A (ja) | 1981-07-27 | 1983-02-02 | Nitsusui Seiyaku Kk | エイコサペンタエン酸トコフエロ−ルエステル |
| JPS5883698A (ja) | 1981-11-13 | 1983-05-19 | Takeda Chem Ind Ltd | キノン化合物およびその製造法 |
| JPS58193689A (ja) | 1982-05-10 | 1983-11-11 | Shiseido Co Ltd | テストステロン−５α−レダクタ−ゼ阻害剤 |
| DK449983A (da) | 1982-10-27 | 1984-04-28 | Hoffmann La Roche | Fremgangsmaade til fremstilling af optiske aktive forbindelser |
| CH655005A5 (it) | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. |
| JPS59163316A (ja) | 1983-03-08 | 1984-09-14 | Eisai Co Ltd | けいれんの治療・予防剤 |
| JPS6028919A (ja) | 1983-07-28 | 1985-02-14 | Shiseido Co Ltd | 皮膚外用剤 |
| EP0134198A1 (de) | 1983-08-10 | 1985-03-13 | Ciba-Geigy Ag | Verwendung von Chinonderivaten zum Schützen von Kulturpflanzen vor der phytotoxischen Wirkung von Herbiziden |
| JPS60197621A (ja) | 1984-03-19 | 1985-10-07 | Hohnen Oil Co Ltd | コレステロ−ル低下剤 |
| US5304658A (en) | 1984-08-01 | 1994-04-19 | Takeda Chemical Industries, Ltd. | Quinone derivatives, their production and use |
| MX9203040A (es) | 1984-08-01 | 1992-07-31 | Takeda Chemical Industries Ltd | Derivados de quinona y composicion farmaceutica que los contiene. |
| JPS6140236A (ja) | 1984-08-02 | 1986-02-26 | Yamanouchi Pharmaceut Co Ltd | ハイドロキノン誘導体 |
| US4592867A (en) | 1984-10-19 | 1986-06-03 | Energy Conversion Devices, Inc. | Synthesis method for reductant precursor |
| US4617317A (en) | 1984-10-31 | 1986-10-14 | Bennet Justin D | Method of treating ulcerative colitis |
| DE3484473D1 (de) | 1984-12-06 | 1991-05-23 | Kuraray Co | Chroman-verbindungen und deren herstellung. |
| US5229385A (en) | 1986-01-30 | 1993-07-20 | Takeda Chemical Industries, Ltd. | Quinone derivatives, their production and use |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| JPH0788376B2 (ja) | 1986-09-02 | 1995-09-27 | エーザイ株式会社 | 光学活性α−トコトリエノ−ルの製造方法 |
| JPH0445016Y2 (enExample) | 1986-10-17 | 1992-10-22 | ||
| GB8626344D0 (en) | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
| US5057514A (en) | 1987-02-03 | 1991-10-15 | Suntory Limited | Compounds effective as cerebral schemia treating agents |
| US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| US5288752A (en) | 1987-12-22 | 1994-02-22 | Suntory Limited | Compound effective as cerebral insufficiency improver |
| US5179092A (en) | 1987-12-22 | 1993-01-12 | Suntory Limited | Compound effective as cerebral insufficiency improver |
| DK36389A (da) | 1988-02-05 | 1989-08-06 | Eastman Kodak Co | Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion |
| JPH01209445A (ja) | 1988-02-17 | 1989-08-23 | Fuji Photo Film Co Ltd | 放射線感応性材料 |
| JP2685785B2 (ja) | 1988-03-11 | 1997-12-03 | エーザイ株式会社 | 光学活性α−トコトリエノールの製造方法 |
| AU618791B2 (en) | 1988-03-16 | 1992-01-09 | Bioindustry Development Centre | Production of high concentration tocopherols and tocotrienols from palm oil by-product |
| DE3818696C1 (en) | 1988-06-01 | 1989-03-30 | Ems-Inventa Ag, Zuerich, Ch | Process for the preparation of hydroquinone and its alkyl derivatives |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| JPH08768B2 (ja) | 1989-08-24 | 1996-01-10 | 武田薬品工業株式会社 | 神経成長因子分泌誘導剤 |
| FI102273B (fi) | 1989-09-11 | 1998-11-13 | Eisai Co Ltd | Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö |
| FR2657345B1 (fr) | 1990-01-19 | 1992-05-07 | Rhone Poulenc Chimie | Procede de c-alkylation de l'hydroquinone et de ses monoethers. |
| US5157132A (en) | 1990-05-18 | 1992-10-20 | Carotech Associates | Integrated process for recovery of carotenoids and tocotrienols from oil |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| ATE132366T1 (de) | 1990-05-29 | 1996-01-15 | Boston Ocular Res | Zusammensetzung zur behandlung von dry eye erkrankungen |
| JP3086284B2 (ja) | 1991-07-05 | 2000-09-11 | 京セラミタ株式会社 | 電子写真感光体 |
| ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| EP0543417A1 (en) | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
| EP0560568A3 (en) | 1992-03-13 | 1994-06-29 | Takeda Chemical Industries Ltd | Hydroquinone derivatives and intermediates for production thereof |
| WO1993024650A1 (en) | 1992-05-28 | 1993-12-09 | Monash University | Therapeutic compositions |
| CN1093360A (zh) | 1992-10-02 | 1994-10-12 | 武田药品工业株式会社 | 2-o-烷基抗坏血酸的锂盐 |
| US5318993A (en) * | 1993-04-16 | 1994-06-07 | Bristol-Myers Squibb Company | Antihyperlipidemic benzoquinones |
| ATE184788T1 (de) | 1993-06-18 | 1999-10-15 | Takeda Chemical Industries Ltd | Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer |
| US5600029A (en) | 1994-03-09 | 1997-02-04 | Takeda Chemical Industries, Ltd. | Process for producing DL-tocopherols and intermediates therefor |
| AU684950B2 (en) | 1994-05-06 | 1998-01-08 | Alcon Laboratories, Inc. | Use of vitamin E tocopheryl derivatives in ophthalmic compositions |
| WO1996004909A1 (en) | 1994-08-12 | 1996-02-22 | Takeda Chemical Industries, Ltd. | Use of quinone and hydroquinone derivatives for the teatment of cachexia |
| US6150402A (en) | 1994-08-15 | 2000-11-21 | Loma Linda University Medical Center | Natriuretic compounds |
| JPH0892151A (ja) | 1994-09-29 | 1996-04-09 | Sagami Chem Res Center | アリルキノンの製造方法 |
| US5547827A (en) | 1994-12-22 | 1996-08-20 | Eastman Kodak Company | Iodochloride emulsions containing quinones having high sensitivity and low fog |
| EP0719552A3 (en) | 1994-12-26 | 1997-08-20 | Takeda Chemical Industries Ltd | Pharmaceutical composition containing a quinone derivative or the hydroquinone thereof for the treatment of dermatitis |
| HU226208B1 (en) | 1994-12-28 | 2008-06-30 | Janssen Pharmaceutica Nv | Use of nebivolol for producing anti-atherogenic pharmaceuticals |
| US5872108A (en) | 1995-03-06 | 1999-02-16 | Interneuron Pharmaceuticals, Inc. | Reduction of infarct volume using citicoline |
| US20030134028A1 (en) | 1995-06-01 | 2003-07-17 | Lipton, Division Of Conopco, Inc. | Fat based food products |
| WO1997007109A1 (en) | 1995-08-21 | 1997-02-27 | Takeda Chemical Industries, Ltd. | Quinone compound, its production and use |
| US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| WO1997035852A1 (en) | 1996-03-25 | 1997-10-02 | Alcon Laboratories, Inc. | Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents |
| DE69712888D1 (de) | 1996-07-11 | 2002-07-04 | Takeda Chemical Industries Ltd | ZUSAMMENSTELLUNGEN DIE beta-AMYLOID PROTEIN BEDINGTE ZYTOTOXIZITÄT VERHINDERN |
| FR2753098B1 (fr) | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
| GB9702310D0 (en) | 1997-02-05 | 1997-03-26 | Univ Hertfordshire | Invention |
| GB9722361D0 (en) | 1997-10-24 | 1997-12-17 | Pharma Nord Uk Ltd | Pharmaceutical formulation for treating liver disorders |
| ID26335A (id) | 1997-11-17 | 2000-12-14 | Lipogenic Inc | Metoda untuk mencegah restenosis dengan menggunakan tokotrienol |
| US6331532B1 (en) | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| EP1051412B1 (en) | 1998-01-29 | 2003-09-24 | Eastman Chemical Company | Methods for separating a tocotrienol from a tocol-containing mixture and compositions thereof |
| US5969133A (en) | 1998-05-22 | 1999-10-19 | Shiongi Bioresearch Corp. | Bioreductive cytotoxic agents |
| US6433199B1 (en) | 1998-05-22 | 2002-08-13 | Shionogi Bioresearch Corporation | Quinone derivatives |
| CN1131217C (zh) | 1998-07-31 | 2003-12-17 | 日本曹达株式会社 | 苯基吡咯化合物和其制备方法及抗高血脂药 |
| US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| IT1304406B1 (it) | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
| US6187811B1 (en) | 1998-10-28 | 2001-02-13 | Lipogenics, Inc. | Methods for treating benign prostatic hyperplasia using tocotrienols |
| CA2272971C (en) | 1998-10-29 | 2008-01-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
| US6562372B1 (en) | 1998-11-06 | 2003-05-13 | Fuji Chemical Industry Co., Ltd. | Tocotrienol-containing powder, a process for preparing it and a tablet comprising compressed said powder into a tablet form |
| US6048891A (en) | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
| JP2000202297A (ja) | 1999-01-20 | 2000-07-25 | Chemiprokasei Kaisha Ltd | 新規な酸化反応用触媒およびそれを用いたｐ―ベンゾキノン類の製造方法 |
| BR0008447A (pt) | 1999-02-23 | 2002-01-15 | Univ California | Métodos de tratamento de distúrbios mitocondriais |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6303801B1 (en) | 1999-03-09 | 2001-10-16 | Sumitomo Chemical Company, Limited | Process for producing alkyl-substituted hydroquinones |
| US6045826A (en) | 1999-04-02 | 2000-04-04 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
| US6632443B2 (en) | 2000-02-23 | 2003-10-14 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
| WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
| US6395915B1 (en) | 1999-09-10 | 2002-05-28 | Technikrom, Inc. | Method for producing purified tocotrienols and tocopherols using liquid chromatography |
| US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| MY127451A (en) | 1999-11-04 | 2006-12-29 | Malaysian Palm Oil Board | A method of chromatographic isolation for vitamin e isomers |
| US8753675B1 (en) | 2000-01-20 | 2014-06-17 | Raj K. Chopra | Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications |
| US6740338B1 (en) | 2000-01-20 | 2004-05-25 | Raj K. Chopra | Reduced form of Cenzyme Q in high bioavailability stable oral dosage form |
| US6346544B2 (en) | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
| WO2001092215A2 (en) | 2000-06-02 | 2001-12-06 | Us Health | Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same |
| DE10034233A1 (de) | 2000-07-14 | 2002-01-24 | Basf Ag | Tocotrienolchinon-Cyclisierungsprodukte |
| US6545184B1 (en) | 2000-08-15 | 2003-04-08 | The Regents Of The University Of California | Practical, cost-effective synthesis of COQ10 |
| US20030206972A1 (en) | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
| PL212952B1 (pl) | 2000-10-26 | 2012-12-31 | Fournier Lab Ireland Ltd | Kompozycja farmaceutyczna zawierajaca fenofibrat i koenzym Q₁₀ oraz jej zastosowanie |
| AUPR177300A0 (en) | 2000-11-29 | 2000-12-21 | Centre For Molecular Biology And Medicine | Therapeutic methods |
| US20020132845A1 (en) | 2000-12-15 | 2002-09-19 | Miller Guy Michael | Compositions and methods for the prevention and treatment of tissue ischemia |
| US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| US6838104B2 (en) | 2000-12-20 | 2005-01-04 | Archer Daniels Midland Company | Process for the production of tocotrienols |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| US6300377B1 (en) | 2001-02-22 | 2001-10-09 | Raj K. Chopra | Coenzyme Q products exhibiting high dissolution qualities |
| US6764768B2 (en) | 2001-02-28 | 2004-07-20 | Arch Development Corporation | Controlled release composition |
| JP2002298952A (ja) | 2001-03-29 | 2002-10-11 | Tyco Electronics Amp Kk | 電気コネクタ |
| US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| JP2003064017A (ja) | 2001-06-12 | 2003-03-05 | Hokko Chem Ind Co Ltd | オキシスチレン誘導体の蒸留方法 |
| US7172905B2 (en) | 2001-08-07 | 2007-02-06 | The University Of Chicago | Polypeptide immobilization |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| AU2002327517B2 (en) | 2001-08-21 | 2008-04-17 | Johnson & Johnson Consumer Companies, Inc. | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| CA2357053A1 (en) | 2001-09-04 | 2003-03-04 | Unknown | Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease |
| JP2003137716A (ja) | 2001-10-30 | 2003-05-14 | Eau De Faveur:Kk | 皮膚の外用剤 |
| US20030144219A1 (en) | 2001-11-15 | 2003-07-31 | Phinney Stephen Dodge | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US20040152764A1 (en) | 2001-12-14 | 2004-08-05 | Miller Guy M. | Compositions and methods for the prevention and treatment of cerebral ischemia |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| US7078541B2 (en) | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
| AT414082B (de) | 2002-05-03 | 2006-09-15 | Vis Vitalis Lizenz & Handels | Verfahren zur herstellung von tocotrienol-angereicherten präparationen |
| DE60211875T2 (de) | 2002-07-01 | 2006-10-26 | Santhera Pharmaceuticals (Schweiz) Ag | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
| US6953331B2 (en) | 2002-08-30 | 2005-10-11 | Extreme Components L.P. | Positioning device with bearing mechanism |
| JP4599292B2 (ja) | 2002-10-30 | 2010-12-15 | エジソン ファーマシューティカルズ， インコーポレイテッド | 物理的−化学的特性に基づく治療用化合物の同定 |
| EP1597276A4 (en) | 2003-02-10 | 2006-11-29 | Autogen Res Pty Ltd | Therapeutic molecules |
| KR20060082791A (ko) | 2003-06-25 | 2006-07-19 | 찰스 에르윈 | 코엔자임 ｑ10의 전달을 증가시키기 위한 화학적 배합물 및방법 |
| JP2007501846A (ja) | 2003-08-08 | 2007-02-01 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | トコトリエノールの予防的使用および治療的使用 |
| AU2004266988B2 (en) | 2003-08-22 | 2011-05-26 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| US7015243B2 (en) | 2003-08-28 | 2006-03-21 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| WO2005032478A2 (en) | 2003-10-01 | 2005-04-14 | Yasoo Health, Inc. | Treatment for diabetic microvascular and macrovascular complications |
| WO2005035491A2 (en) | 2003-10-10 | 2005-04-21 | Yasoo Health, Inc. | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND |
| MXPA06009529A (es) | 2004-02-23 | 2007-04-10 | Texas A & M Univ Sys | Composiciones antioxidantes y metodos para el uso de las mismas. |
| US7022441B2 (en) | 2004-02-25 | 2006-04-04 | Eastman Kodak Company | Silver-free black-and-white thermographic materials containing a benzoquinone and methods of imaging |
| US20050256186A1 (en) | 2004-03-05 | 2005-11-17 | Fumie Morishige | Prevention of and countermeasures against mitochondrial disease |
| WO2005090602A2 (en) | 2004-03-18 | 2005-09-29 | Sucampo Ag | Method for diagnosing or predicting susceptibility to optic nueropathy |
| US7485283B2 (en) | 2004-04-28 | 2009-02-03 | Lantheus Medical Imaging | Contrast agents for myocardial perfusion imaging |
| WO2005115478A2 (en) | 2004-05-11 | 2005-12-08 | The Regents Of The University Of California | Methods and compositions for autism spectrum disorders |
| EP1611879B1 (en) | 2004-07-02 | 2009-08-12 | Novagali Pharma SA | Use of emulsions for intra- and periocular injection |
| DE102004032837A1 (de) | 2004-07-02 | 2006-02-09 | Beiersdorf Ag | Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| JP5150807B2 (ja) | 2005-02-28 | 2013-02-27 | 株式会社明治 | ハイドロキノン長鎖誘導体及び／又はフェノキシ長鎖誘導体及びこれらを含有する医薬 |
| US20060241174A1 (en) | 2005-04-22 | 2006-10-26 | Anne Mueller | Vitamin E tocotrienols inhibition of intracellularly obligate pathogen Chlamydia and methods of use |
| EA035619B1 (ru) | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| RU2403272C2 (ru) | 2005-06-30 | 2010-11-10 | Киова Кемикал Индастри Ко., Лтд. | Антибактериальное средство, состоящее из серебросодержащих частиц гидроксида сульфата алюминия, и его применение |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| JP5122460B2 (ja) | 2005-09-16 | 2013-01-16 | アラーガン、インコーポレイテッド | 治療薬の眼内輸送のための組成物および方法 |
| US20070248590A1 (en) | 2005-12-02 | 2007-10-25 | Sirtris Pharmaceuticals, Inc. | Modulators of CDC2-like kinases (CLKS) and methods of use thereof |
| WO2007095630A2 (en) | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | New ubiquinone analogs and methods of use |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| JPWO2007116750A1 (ja) | 2006-03-30 | 2009-08-20 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子用材料、及びこれを用いた有機エレクトロルミネッセンス素子 |
| WO2008086025A2 (en) | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| WO2008157747A1 (en) | 2007-06-21 | 2008-12-24 | The Jackson Laboratory | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders |
| EP2187743B1 (en) | 2007-08-16 | 2014-07-30 | Santen Pharmaceutical Co., Ltd | Rapamycin formulations for treatment of age related macular degeneration |
| US8075909B2 (en) | 2007-09-04 | 2011-12-13 | University Of Florida Research Foundation, Incorporated | Contact lens based bioactive agent delivery system |
| PL2220030T3 (pl) | 2007-11-06 | 2016-07-29 | Bioelectron Tech Corp | Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych |
| WO2009088572A2 (en) | 2008-01-07 | 2009-07-16 | Centocor, Inc. | Method of treating erythropoietin hyporesponsive anemias |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2262519A4 (en) | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS |
| EP2310038A4 (en) | 2008-05-15 | 2012-03-14 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT |
| WO2009143268A2 (en) | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| WO2010005989A1 (en) | 2008-07-09 | 2010-01-14 | Edison Pharmaceuticals, Inc. | Dermatological compositions with anti-aging and skin even-toning properties |
| WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
| US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| JP5731980B2 (ja) | 2008-10-09 | 2015-06-10 | ラムズコア， インコーポレイテッド | ドライアイ症候群の処置のための組成物および方法 |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| CA2777479C (en) | 2009-04-28 | 2017-10-17 | Ptc Therapeutics, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| WO2010126910A1 (en) | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
| EA201101576A1 (ru) | 2009-04-28 | 2012-04-30 | Эдисон Фармасьютикалз, Инк. | Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний |
| JP2012531411A (ja) | 2009-06-25 | 2012-12-10 | アンペア ライフ サイエンシーズ，インコーポレイテッド | トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置 |
| NO2470168T3 (enExample) | 2009-08-26 | 2018-06-30 | ||
| WO2011041452A2 (en) | 2009-10-01 | 2011-04-07 | Ampere Life Sciences, Inc. | Mouse model for identifying compounds for the treatment of oxidative stress |
| CA2797644A1 (en) | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
| EA201201374A1 (ru) | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
| AU2011245384C1 (en) | 2010-04-27 | 2016-09-01 | Bioelectron Technology Corporation | Formulations of quinones for the treatment of ophthalmic diseases |
| WO2012009271A1 (en) | 2010-07-14 | 2012-01-19 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
| WO2012019032A1 (en) | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
| US20130345312A1 (en) | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| ES2795798T3 (es) | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
| CA2842486C (en) | 2011-07-19 | 2022-09-06 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| JP2016515526A (ja) | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| WO2014194292A1 (en) | 2013-05-31 | 2014-12-04 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
| EP3233819A1 (en) | 2014-12-16 | 2017-10-25 | Bioelectron Technology Corporation | Methods for chiral resolution of trolox |
| HUE058877T2 (hu) | 2014-12-16 | 2022-09-28 | Ptc Therapeutics Inc | (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| US20190241497A1 (en) | 2016-10-28 | 2019-08-08 | Andrew W. Hinman | Methods for analyzing p-hydroquinone levels and ratios |
| WO2018093957A1 (en) | 2016-11-15 | 2018-05-24 | Bioelectron Technology Corporation | 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications |
-
2006
- 2006-06-01 EA EA201101668A patent/EA035619B1/ru not_active IP Right Cessation
- 2006-06-01 HU HUE12162555A patent/HUE033304T2/en unknown
- 2006-06-01 CA CA2996149A patent/CA2996149A1/en not_active Abandoned
- 2006-06-01 EP EP12195108.1A patent/EP2564843B1/en not_active Expired - Lifetime
- 2006-06-01 DK DK12195108.1T patent/DK2564843T3/en active
- 2006-06-01 EP EP12162555.2A patent/EP2471530B1/en not_active Expired - Lifetime
- 2006-06-01 ES ES12162555.2T patent/ES2619303T3/es not_active Expired - Lifetime
- 2006-06-01 PL PL06784530T patent/PL1888059T3/pl unknown
- 2006-06-01 EP EP06784530.5A patent/EP1888059B1/en not_active Expired - Lifetime
- 2006-06-01 EP EP12195101A patent/EP2564842A1/en not_active Withdrawn
- 2006-06-01 DK DK06784530.5T patent/DK1888059T3/en active
- 2006-06-01 PT PT67845305T patent/PT1888059E/pt unknown
- 2006-06-01 PT PT121625552T patent/PT2471530T/pt unknown
- 2006-06-01 ES ES12195108T patent/ES2714900T3/es not_active Expired - Lifetime
- 2006-06-01 CA CA2610152A patent/CA2610152C/en not_active Expired - Lifetime
- 2006-06-01 PL PL12195108T patent/PL2564843T3/pl unknown
- 2006-06-01 MX MX2012009599A patent/MX359292B/es unknown
- 2006-06-01 MX MX2007015006A patent/MX2007015006A/es active IP Right Grant
- 2006-06-01 US US11/445,582 patent/US9447006B2/en active Active
- 2006-06-01 JP JP2008514860A patent/JP2008542389A/ja not_active Withdrawn
- 2006-06-01 WO PCT/US2006/021295 patent/WO2006130775A2/en not_active Ceased
- 2006-06-01 ES ES06784530.5T patent/ES2532912T3/es not_active Expired - Lifetime
- 2006-06-01 PL PL12162555T patent/PL2471530T3/pl unknown
- 2006-06-01 EA EA200702622A patent/EA016226B1/ru not_active IP Right Cessation
- 2006-06-01 SI SI200631901T patent/SI1888059T1/sl unknown
- 2006-06-01 DK DK12162555.2T patent/DK2471530T3/en active
-
2010
- 2010-05-10 US US12/777,179 patent/US11021424B2/en active Active
- 2010-10-19 MX MX2010011492A patent/MX2010011492A/es active IP Right Grant
-
2012
- 2012-09-21 JP JP2012207828A patent/JP2012250997A/ja active Pending
-
2013
- 2013-02-20 JP JP2013030630A patent/JP5631428B2/ja not_active Expired - Lifetime
-
2014
- 2014-06-20 JP JP2014126926A patent/JP2014169334A/ja not_active Withdrawn
-
2015
- 2015-11-25 JP JP2015229350A patent/JP2016029112A/ja not_active Withdrawn
-
2017
- 2017-10-05 JP JP2017195027A patent/JP2018002736A/ja not_active Withdrawn
-
2021
- 2021-05-28 US US17/334,601 patent/US20220055975A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006130775A3 (en) | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers | |
| WO2007100652A3 (en) | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | |
| MX338572B (es) | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. | |
| EA201001119A1 (ru) | Производные (гет)арил-п-хинона для лечения митохондриальных болезней | |
| WO2012019029A3 (en) | Treatment of mitochondrial diseases with naphthoquinones | |
| CY1123740T1 (el) | Παραλλαγες ακρων δραστικων οξειοδοαναγωγικων θεραπειων για αγωγη σε μιτοχονδριακες νοσους και αλλες καταστασεις και ρυθμιση των ενεργειακων βιοδεικτων | |
| CY1124526T1 (el) | Συνθεσεις για τη ρυθμιση της εκφρασης αταξινης -2 | |
| CY1114712T1 (el) | Υδατικες φαρμακευτικες συνθεσεις περιεχουσες συμπλοκα βορικου-πολυολης | |
| ATE439863T1 (de) | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie | |
| CY1119509T1 (el) | Συνθεσεις και μεθοδοι για ρυθμιστες αποπτωσης | |
| ATE408412T1 (de) | Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration | |
| BRPI0821229A2 (pt) | composição para cuidados pessoais, método para o tratamento de condicionamento de fibras contendo queratina de mamíferos, e, terpolímero catiônico | |
| BR0315437A (pt) | Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos | |
| MX2018007389A (es) | Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo. | |
| DE602004013439D1 (de) | Ildung mit 4-hydroxy tamoxifen | |
| ATE396982T1 (de) | Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors | |
| MX2010001303A (es) | Compuestos terapeuticos. | |
| HK1149450A (en) | (het) aryl-p-quinone derivatives for treatment of mitochondrial diseases | |
| MA26397A1 (fr) | Protege-orteils, particulierement pour chaussures de securite. | |
| ATE397000T1 (de) | Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs | |
| MX2013012197A (es) | Un compuesto de silicon y composiciones para cuidado personal fotoprotectoras que comprenden el mismo. | |
| GEAP202516423A (en) | Kcnv2 variants and their use | |
| Xu et al. | Benchmarking the effects of the Fed's Secondary Market Corporate Credit Facility using Yankee bonds | |
| TR201821258T4 (tr) | Mitokondrial hastalıkların ve diğer durumların tedavisi ve enerji biyobelirteçlerinin modülasyonu için redoks aktif terapötikler. | |
| FR3068885B1 (fr) | Composition cosmetique anti-age |